Home › Research › Biomarkers
A Survey of Knowledge and Views Concerning Genetic and Amyloid PET Status Disclosure
Ott BR, Pelosi MA, Tremont G, Snyder PJ.. Alzheimer's & dementia (New York, N. Y.), 2016-01-01
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Introduction This survey characterizes viewpoints of cognitively intact at-risk participants in an Alzheimer prevention registry if given the opportunity to learn their genetic and amyloid PET status. Methods 207 participants were offered a 25-item survey. They were asked if they wished to know their ApoE and amyloid PET status, and if so, reasons for wanting to know, or not, and the effects of such information on life plans. Results 164 (79.2%) of registrants completed the survey. Among those who were unaware of their ApoE or amyloid PET results, 80% desired to know this information. The most common reasons for wanting disclosure were to participate in research, to arrange personal affairs, to prepare family for illness, and to move life plans closer into the future. When asked if disclosure would help with making plans to end one's life when starting to lose their memory, 12.7% vs. 11.5% responded yes for ApoE and amyloid PET disclosures, respectively. Disclosure of these test results, if required for participation in a clinical trial, would make 15% of people less likely to participate. Likelihood of participation in prevention research and the desire to know test results were not related to scores on brief tests of knowledge about the tests. Discussion These results suggest that stakeholders in AD prevention research generally wish to know biological test information about their risk for developing AD to assist in making life plans.
What this study adds
Evidence grade: Low
The record lists 207 participants. About 15% said disclosure of these test results, if required for a clinical trial, would make them less likely to participate, so this survey addresses attitudes toward testing rather than any treatment, cure, or prevention. Reported effect size: 79.2%; 12.7%; 11.5%.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Ott, B. R., Pelosi, M. A., Tremont, G., & Snyder, P. J. (2016). A Survey of Knowledge and Views Concerning Genetic and Amyloid PET Status Disclosure. Alzheimer's & dementia (New York, N. Y.). https://doi.org/10.1016/j.trci.2015.12.001
Vancouver
Ott BR, Pelosi MA, Tremont G, Snyder PJ. A Survey of Knowledge and Views Concerning Genetic and Amyloid PET Status Disclosure. Alzheimer's & dementia (New York, N. Y.). 2016. doi:10.1016/j.trci.2015.12.001. PMID: 27019867.
BibTeX
@article{ott2016-27019867,
author = {Ott, B. R. and Pelosi, M. A. and Tremont, G. and Snyder, P. J.},
title = {{A Survey of Knowledge and Views Concerning Genetic and Amyloid PET Status Disclosure}},
journal = {Alzheimer's \& dementia (New York, N. Y.)},
year = {2016},
doi = {10.1016/j.trci.2015.12.001},
pmid = {27019867},
url = {https://doi.org/10.1016/j.trci.2015.12.001}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Results 164 (79.2%) of registrants completed the survey.
- Among those who were unaware of their ApoE or amyloid PET results, 80% desired to know this information.
- Disclosure of these test results, if required for participation in a clinical trial, would make 15% of people less likely to participate.
- Likelihood of participation in prevention research and the desire to know test results were not related to scores on brief tests of knowledge about the tests.
- Discussion These results suggest that stakeholders in AD prevention research generally wish to know biological test information about their risk for developing AD to assist in making life plans.
Why it matters
In a survey of cognitively intact at-risk participants in an Alzheimer prevention registry, 80% of those unaware of their ApoE or amyloid PET results wanted to know this information, most commonly to participate in research, arrange personal affairs, prepare family for illness, and move life plans closer. About 15% said disclosure of these test results, if required for a clinical trial, would make them less likely to participate, so this survey addresses attitudes toward testing rather than any treatment, cure, or prevention.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Participants207
- Effect size79.2%; 12.7%; 11.5%
- Evidence strengthLow
How this study scored 49/100
Published in a leading specialty journal. Scored zero for study design and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Alzheimer's & dementia (New York, N. Y.)) |
| Journal's citation record | 1 / 4 | Alzheimer s & Dementia Translational Research & Clinical Interventions: journal h-index 84 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2016 — within 20 year(s) of the newest study here |
| Sample size | 2 / 4 | 207 participants |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 4 / 7 | Cited 46 times (OpenAlex, 2026-10-10) |
| Citations per year | 2 / 5 | 3.8 citations a year over 12 year(s) since 2016 |
| Impact for its field and year | 2 / 6 | Cited 1.8× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 2 / 6 | Cited by 4 other studies in this library |
| Still being cited | 1 / 4 | Cited 13 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Peter Jeffrey Snyder: h-index 88 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | Brown University: institution h-index 1,120 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 2 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 27019867) |
| Free to read | 2 / 2 | Free to read |
| Total | 49 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — PubMed Central lists this copy as free to read: the link above (checked 10 Oct 2026).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
4 studies in the alzhub library list this one in their references.
Related studies in Biomarkers from nearby years
Also tagged “machine”
834 studies in the library carry the topic tag “machine”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 834 tagged studies.